Prophylaxis

Prophylaxis

People with von Willebrand disease (VWD) are at increased risk of bleeding, which may manifest as frequent nosebleeds, easy bruising, prolonged bleeding from minor cuts, excessive bleeding during dental treatment, and heavy menstrual bleeding.1


Prophylaxis with a von Willebrand factor (VWF) concentrate is recommended to prevent bleeding in people with severe von Willebrand disease.2, 3 wilate® prophylaxis is effective in adults, adolescents and children with all von Willebrand disease types, reducing the rate of bleeding compared with on-demand treatment.4

von Willebrand factor prophylaxis

in people with von Willebrand disease

Prophylaxis with VWF concentrates*

* Prevention and treatment of haemorrhage or surgical bleeding in von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contra-indicated.

Can effectively
prevent bleeding2

May reduce the burden of von Willebrand disease and improve quality of life2

Is recommended in patients with severe von Willebrand disease4

von Willebrand factor prophylaxis

in people with von Willebrand disease

A significant proportion of people with
von Willebrand disease may be undertreated2

of patients with severe von Willebrand disease receive prophylaxis with VWF concentrates5

Clinical experience with wilate®

prophylaxis in von Willebrand disease

Efficacy of wilate® prophylaxis has been demonstrated in

Prospective clinical trials in adults4 and children4,6

Real-world clinical practice7-9

wilate® prophylaxis

reduced the bleeding rate compared with previous treatment in children, adolescents and adults4

Data from 4 prospective, multicentre Phase II/III trials

2-1_5@2x
19 patients on wilate® prophylaxis
Aged 5–73 years

wilate® prophylaxis

reduced the bleeding rate compared with previous treatment in children, adolescents and adults4

Data from 4 prospective, multicentre Phase II/III trials

of patients had
type 3 VWD

median (range 3-46 months) duration of prophylaxis

wilate® prophylaxis

reduced the bleeding rate compared with previous treatment in children, adolescents and adults4

Data from 4 prospective, multicentre Phase II/III trials

Bleeding frequency significantly reduced after the start of wilate® prophylaxis

Information about on-demand treatment with wilate®


Treat on-demand

Surgical prophylaxis with wilate®


Prepare for surgery

Use of wilate® in people with von Willebrand disease


Tolerability

References

  1. de Wee EM et al. Thromb Haemost 2012; 108:683-92.
  2. Miesbach W and Berntorp E. Thromb Res 2021; 199:67-74.
  3. Connell NT et al. Blood Adv 2021; 5:301-25.
  4. Berntorp E et al. Haemophilia 2009; 15:122-30.
  5. wilate® SmPC, updated June 2021.
  6. Nowak-Göttl U et al. Haemophilia 2013; 19:887-92.
  7. Halimeh S et al. Thromb Haemost 2011; 105:597-604.
  8. Khair K et al. Presented at ISTH 2019 (Poster PB0808).
  9. Sholzberg M et al. TH Open 2021; 5:e264-72.

TEST footer